Actimed Therapeutics is developing pharmacological treatments for cachexia and other muscle-wasting conditions, utilizing compounds like S-oxprenolol to target metabolic dysregulation in affected patients. The company aims to improve the quality of life for individuals suffering from these conditions, which often lead to significant physical decline and diminished dignity.
Funding
$24.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cachexia and other muscle-wasting conditions lead to significant physical decline, reduced quality of life, and increased burden on patients, caregivers, and healthcare providers. These conditions are often under-served, leaving a vulnerable patient population with limited treatment options.
Solution
Actimed Therapeutics is developing pharmacological treatments targeting the metabolic dysregulation underlying cachexia and other muscle-wasting conditions. Their compounds, such as S-oxprenolol (ACM-002), aim to improve the quality of life for affected individuals by addressing the root causes of muscle loss. The company's vision is to transform care for this patient population, prolonging and improving their lives, restoring their dignity, and easing the burden on all stakeholders.
Target Audience
The primary target audience includes patients suffering from cachexia and other muscle-wasting conditions, as well as their caregivers and healthcare providers.
Features
- Focus on pharmacological treatments for cachexia and muscle-wasting conditions.
- Utilizing compounds like S-oxprenolol (ACM-002) to target metabolic dysregulation.
- Aims to improve the quality of life for patients suffering from these conditions.
- S-oxprenolol (ACM-002) has received Orphan Drug Designation from the US FDA for the treatment of Amyotrophic Lateral Sclerosis (ALS).